A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
Public ClinicalTrials.gov record NCT02788279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma
Study identification
- NCT ID
- NCT02788279
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 363 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody Drug
- Cobimetinib Drug
- Regorafenib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 4, 2016
- Primary completion
- Mar 8, 2018
- Completion
- Dec 25, 2018
- Last update posted
- Dec 10, 2019
2016 – 2018
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| Yale Cancer Center; Medical Oncology | New Haven | Connecticut | 06520 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Florida Cancer Specialists; SCRI | Fort Myers | Florida | 33901 | — |
| Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy) | Jacksonville | Florida | 32256 | — |
| Florida Cancer Specialists. | St. Petersburg | Florida | 33705 | — |
| Ingalls Cancer Research Center | Harvey | Illinois | 60426 | — |
| Southdale Cancer Clinic U of M Medical Center, Fairview- Edina | Edina | Minnesota | 55435 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| North Shore Hem Onc Associates | East Setauket | New York | 11733 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| INTEGRIS Cancer Inst of OK | Oklahoma City | Oklahoma | 73142 | — |
| University of Pittsburgh Cancer Institute; Division of Medical Oncology | Pittsburgh | Pennsylvania | 15232 | — |
| SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Research Inst. | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Medical Oncology Associates | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02788279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2019 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02788279 live on ClinicalTrials.gov.